Switching to piperacillin-tazobactam for prophylaxis significantly lowers surgical site infections and pancreatic fistula rates in open pancreatoduodenectomy.

• Patients on piperacillin-tazobactam had 30% fewer surgical site infections and pancreatic fistulas compared to those on cefoxitin.
• The switch is backed by data from over 4,000 patients, with a clear trend toward piperacillin-tazobactam usage increasing.

Consider adopting piperacillin-tazobactam to enhance perioperative outcomes for your patients.